Mirvetuximab for folate-receptor–positive endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 study tests mirvetuximab (a targeted antibody drug) in women whose endometrial cancer is positive for folate receptor-alpha. It aims to shrink tumors and improve outcomes, especially in cancer that has returned or kept growing after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your endometrial cancer is proven by scans (CT/MRI) to be persistent or recurrent
- Your tumor type and grade must match specific kinds (serous, carcinosarcoma with certain features, grade 2–3 adenocarcinoma, or clear cell)
- Your tumor must test positive for folate receptor-alpha (FRα) using the study’s testing rules
- You have at least one measurable tumor spot that doctors can track on scans
- You’ve had 0–3 prior treatment “lines” for the recurrent cancer (hormone therapy doesn’t count as a line)
- Your health tests are adequate (blood counts, liver, kidney) and you can do daily activities (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted drug (fruquintinib) to standard chemotherapy works better than chemotherapy alone as the first treatment for advanced or recurrent endometrial cancer that is pMMR. It may help control the cancer for a longer time.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a drug called EV for people with recurrent endometrial cancer that has gotten worse after treatment. It may help if your cancer cells have a specific protein called nectin-4.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This study is testing a drug called mirvetuximab soravtansine (MIRV) in real-world conditions for people with a specific type of ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see how well the drug works and what side effects occur in everyday practice.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.